| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥65M | ¥138M | -52.9% |
| Cost of Sales | ¥33M | ¥59M | -44.3% |
| Gross Profit | ¥32M | ¥79M | -59.2% |
| SG&A Expenses | ¥857M | ¥743M | +15.3% |
| Operating Income | ¥-824M | ¥-664M | -24.1% |
| Non-operating Income | ¥3M | ¥673,000 | +371.3% |
| Non-operating Expenses | ¥2M | ¥6M | -61.0% |
| Ordinary Income | ¥-823M | ¥-669M | -23.0% |
| Profit Before Tax | ¥-848M | ¥-678M | -25.1% |
| Income Tax Expense | ¥2M | ¥2M | +0.0% |
| Net Income | ¥-849M | ¥-679M | -25.0% |
| Interest Expense | ¥1M | ¥2M | -5.5% |
| Basic EPS | ¥-24.51 | ¥-20.58 | -19.1% |
| Dividend Per Share | ¥0.00 | ¥0.00 | - |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥1.53B | ¥2.31B | ¥-780M |
| Cash and Deposits | ¥1.37B | ¥2.13B | ¥-764M |
| Accounts Receivable | ¥22M | ¥37M | ¥-15M |
| Inventories | ¥21M | ¥12M | +¥8M |
| Non-current Assets | ¥134M | ¥121M | +¥13M |
| Item | Value |
|---|---|
| Net Profit Margin | -1306.2% |
| Gross Profit Margin | 49.6% |
| Current Ratio | 727.5% |
| Quick Ratio | 717.7% |
| Debt-to-Equity Ratio | 0.27x |
| Interest Coverage Ratio | -562.46x |
| Effective Tax Rate | -0.2% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | -52.8% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 34.67M shares |
| Treasury Stock | 156 shares |
| Average Shares Outstanding | 34.67M shares |
| Book Value Per Share | ¥37.82 |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥0.00 |
| Year-End Dividend | ¥0.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| CellSheetRegenerativeMedicine | ¥2M | ¥-578M |
| LaboratoryConsumableEquipment | ¥63M | ¥-80M |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥80M |
| Operating Income Forecast | ¥-1.04B |
| Ordinary Income Forecast | ¥-1.04B |
| Net Income Forecast | ¥-1.09B |
| Basic EPS Forecast | ¥-31.59 |
| Dividend Per Share Forecast | ¥0.00 |
| Total Assets | ¥1.67B | ¥2.43B | ¥-768M |
| Current Liabilities | ¥211M | ¥103M | +¥107M |
| Accounts Payable | ¥1M | ¥6M | ¥-5M |
| Non-current Liabilities | ¥144M | ¥167M | ¥-23M |
| Long-term Loans | ¥110M | ¥133M | ¥-23M |
| Total Liabilities | ¥354M | ¥270M | +¥85M |
| Total Equity | ¥1.31B | ¥2.16B | ¥-852M |
| Capital Stock | ¥2.15B | ¥2.82B | ¥-667M |
| Capital Surplus | ¥1.80B | ¥1.80B | ¥0 |
| Retained Earnings | ¥-850M | ¥-2.47B | +¥1.62B |
| Treasury Stock | ¥-227,000 | ¥-227,000 | ¥0 |
| Owners' Equity | ¥1.30B | ¥2.15B | ¥-849M |
| Working Capital | ¥1.32B | - | - |